Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 26.84% is 203% above its 5-year average of -25.95%, near the high end of its 5-year range (-68.09%–26.84%).
As of the fiscal period ended Tuesday, June 30, 2026. 328.95% above its 12-month average of -11.72%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 26.84%.
RETURN ON EQUITY (ROE)
26.84%
RETURN ON EQUITY (ROE) AVG TTM
-11.72%
RETURN ON EQUITY (ROE) AVG 3Y
-13.02%
RETURN ON EQUITY (ROE) AVG 5Y
-25.95%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+328.95%
CURRENT VS 3Y AVG
+306.11%
CURRENT VS 5Y AVG
+203.44%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
13.01%
median of 84 covered companies
CURRENT VS SECTOR MEDIAN
+106.29%
vs the sector median at left
Oscar Health, Inc.
Market Cap
$8.33B
Return on Equity (ROE)
26.84%
TTM Avg
-11.72%
3Y Avg
-13.02%
5Y Avg
-25.95%
Market Cap
$9.66B
Return on Equity (ROE)
12.77%
TTM Avg
11.88%
3Y Avg
12.69%
5Y Avg
13.50%
Market Cap
$9.74B
Return on Equity (ROE)
26.39%
TTM Avg
25.41%
3Y Avg
19.99%
5Y Avg
14.02%
Market Cap
$9.99B
Return on Equity (ROE)
11.23%
TTM Avg
7.12%
3Y Avg
6.90%
5Y Avg
7.16%
Market Cap
$6.59B
Return on Equity (ROE)
33.11%
TTM Avg
27.03%
3Y Avg
27.48%
5Y Avg
31.41%
Market Cap
$10.13B
Return on Equity (ROE)
3.10%
TTM Avg
-8.94%
3Y Avg
-15.72%
5Y Avg
1.14%
Market Cap
$10.14B
Return on Equity (ROE)
15.51%
TTM Avg
15.81%
3Y Avg
15.92%
5Y Avg
17.27%
Market Cap
$6.24B
Return on Equity (ROE)
-43.83%
TTM Avg
25.09%
3Y Avg
5.57%
5Y Avg
0.40%
Market Cap
$10.48B
Return on Equity (ROE)
-0.17%
TTM Avg
18.91%
3Y Avg
22.60%
5Y Avg
24.60%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oscar Health, Inc. (OSCR) | $8.33B | 26.84% | -11.72% | -13.02% | -25.95% |
| Henry Schein, Inc. (HSIC)vs › | $9.66B | 12.77% | 11.88% | 12.69% | 13.50% |
| Insulet Corp. (PODD)vs › | $9.74B | 26.39% | 25.41% | 19.99% | 14.02% |
| Globus Medical, Inc. (GMED)vs › | $9.99B | 11.23% | 7.12% | 6.90% | 7.16% |
| Chemed Corporation (CHE)vs › | $6.59B | 33.11% | 27.03% | 27.48% | 31.41% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $10.13B | 3.10% | -8.94% | -15.72% | 1.14% |
| The Ensign Group, Inc. (ENSG)vs › | $10.14B | 15.51% | 15.81% | 15.92% | 17.27% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.24B | -43.83% | 25.09% | 5.57% | 0.40% |
| Molina Healthcare, Inc. (MOH)vs › | $10.48B | -0.17% | 18.91% | 22.60% | 24.60% |
| Align Technology, Inc. (ALGN)vs › | $10.57B | 9.77% | 10.54% | 10.84% | 19.93% |
ROE
26.8%
ROA
4.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 26.84% |
| 2026-03-31 | -2.37% |
| 2025-12-31 | -45.33% |
| 2025-09-30 | -23.83% |
| 2025-06-30 | -13.92% |
| 2025-03-31 | 9.25% |
| 2024-12-31 | 2.51% |
| 2024-09-30 | 2.49% |
| 2024-06-30 | 1.59% |
| 2024-03-31 | -5.19% |
| 2023-12-31 | -33.67% |
| 2023-09-30 | -37.71% |
| 2023-06-30 | -49.94% |
| 2023-03-31 | -61.41% |
| 2022-12-31 | -68.09% |
| 2022-09-30 | -53.57% |
| 2022-06-30 | -48.04% |
| 2022-03-31 | -41.99% |
| 2021-12-31 | -41.31% |
| 2021-09-30 | -36.28% |
| 2021-06-30 | -24.87% |
| 2021-03-31 | -22.33% |
